Differential Analysis and Application Prospects of DNA Tumor Biomarkers in The Five Major Types of Tumors
DOI:
https://doi.org/10.62051/nx0rwq41Keywords:
Tumor biomarkers; DNA; differential analysis; detection techniques; clinical applications.Abstract
With the increasing global burden of cancer, the study of tumor biomarkers (TMs) is of great significance as key tools for early diagnosis, disease monitoring, treatment efficacy evaluation, and prognosis judgment of cancer. This study focuses on the five major tumor types: lung cancer, colorectal cancer, liver cancer, female breast cancer, and gastric cancer. By screening and integrating relevant data on the clinVar website, this article classified, quantified, and analyzed the differences in DNA TMs identified in the five major tumor types mentioned above. In addition, this article explores the mechanisms and principles of DNA tumor biomarker types with relative commonality and specificity in tumor formation and spread among the five major tumor types. We found that the mechanism characteristics of common TMs in the five major tumor types are relatively concentrated; The mechanism characteristics of TMs unique to the five major tumor types are more dispersed. The frequency of occurrence of DNA tumor biomarker mechanism classification has a certain directional effect on tumor types and has a positive impact on the judgment of tumor types. This study aims to provide theoretical support for the discovery, refinement, and personalized clinical application of more TMs in the future, and to improve the survival rate and quality of life of cancer patients.
Downloads
References
[1] Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y, et al. Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduction and Targeted Therapy, 2024, 9(1).
[2] Bray F, Laversanne M, Sung H, Ferlay J, Siegel R L, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 2024, 74(3): 229–263.
[3] ClinVar. ClinVar. https://www.ncbi.nlm.nih.gov/clinvar/, [n.d.].
[4] Li B, Zhang G, Xu X. APC mutation correlated with poor response of immunotherapy in colon cancer. BMC Gastroenterology, 2023, 23(1).
[5] Saelee P, Pongtheerat T. APC promoter hypermethylation as a prognostic marker in breast cancer patients. Asian Pacific Journal of Cancer Prevention, 2020, 21(12): 3627–3632.
[6] Xu L Y, Chen X L, Zhang W J. The role and research progress of breast cancer susceptibility gene 1 in colorectal cancer. Oncology Progress, 2023, 21(11): 1167-1170+1199.
[7] Tao F. Deletion level and value analysis of MLH1 and PMS2 in gastric cancer tissues. China Modern Doctor, 2024, 62(15): 24-28.
[8] Chai C, Maran S, Thew H, et al. Predicting deleterious non-synonymous single nucleotide polymorphisms (nsSNPs) of HRAS gene and in silico evaluation of their structural and functional consequences towards diagnosis and prognosis of cancer. Biology, 2022, 11(11): 1604.
[9] Krop I E, Mayer E L. PIK3CA mutations in breast cancer: clinical significance and therapeutic implications. Journal of Clinical Oncology, 2021, 39(6): 612-620.
[10] Geyer S, Reis-Filho J S. The role of TP53 mutations in breast cancer: Implications for prognosis and treatment. Journal of Pathology, 2021, 253(4): 402-411.
[11] Ou S H I, Szabo E. TP53 mutations in lung cancer: Clinical relevance and potential therapies. Journal of Thoracic Oncology, 2021, 16(5): 757-771.
[12] Wu X, et al. Associations between MTHFR C677T polymorphisms and breast cancer risk: A systematic review and meta-analysis. BMC Cancer, 2021, 21: 287.
[13] Zehir A, Benayed R, Shah R H, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23(6): 703–713.
[14] Cohen J D, Diergaarde B, Papadopoulos N, Kinzler K W, Schoen R E. Tumor DNA as a cancer biomarker through the lens of colorectal neoplasia. Cancer Epidemiology Biomarkers & Prevention, 2020, 29(12): 2441–2453.
[15] Sun C Y, Zhao D B. The progress and future prospects of the application of circulating tumor DNA in the diagnosis and treatment of gastric cancer. China Oncology, 2023, 33(08): 782-789.
Downloads
Published
Conference Proceedings Volume
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







